RESPIRATORY DISTRESS SYNDROME IN INFANTS- AN OVERVIEW

Authors

  • Ghayathri Vijaya Kumaran Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical Sciences, Chennai, India. Author
  • Gowri Sethu Professor and Head, Department of Physiology, Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical Sciences, Chennai, India. Author
  • Dhanraj Ganapathy Professor and Head, Department of Prosthodontics, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Chennai, India Author

DOI:

https://doi.org/10.61841/fz8n1k96

Keywords:

Respiratory distress syndrome, surfactant, hyaline membrane disease, tachypnea, tachycardia, chest wall retractions (recession), expiratory grunting, nasal flaring, cyanosis, glycoproteins, pneumocytes, air-bronchograms, glucocorticoid

Abstract

Respiratory distress syndrome (RDS) is a breathing disorder that affects newborns. RDS rarely occurs in full-term infants. The disorder is more common in premature infants born about 6 weeks or more before their due dates. In fact, nearly all infants born before 28 weeks of pregnancy develop RDS. RDS is more common in premature infants because their lungs aren't able to make enough surfactant (sur-FAK-tant). A surfactant is a liquid that coats the inside of the lungs. It helps keep them open so that infants can breathe in air once they're born. Without enough surfactant, the lungs collapse, and the infant has to work hard to breathe. He or she might not be able to breathe in enough oxygen to support the body's organs. The lack of oxygen can damage the baby's brain and other organs if proper treatment isn't given. Most babies who develop RDS show signs of breathing problems and a lack of oxygen at birth or within the first few hours that follow. Due to improved treatments and medical advances, most infants who have RDS survive. However, these babies may need extra medical care after going home. Some babies have complications from RDS or its treatments. Serious complications include chronic (ongoing) breathing problems, such as asthma and BPD; blindness; and brain damage. This paper will outline the clinical course and diagnosis and treatment for the same and also will draw a simple conclusion. 

Downloads

Download data is not yet available.

References

1. Northway WH, Rosan RC, Porter DY. Pulmonary Disease Following Respirator Therapy of Hyaline HyalineMembrane Disease. New England Journal of Medicine 1967;276:357–68.

https://doi.org/10.1056/nejm196702162760701.

2. Schwartz RM, Luby AM, Scanlon JW, Kellogg RJ. Effect of Surfactant on Morbidity, Mortality, and

Resource Use in Newborn Infants Weighing 500 to 1500 g. New England Journal of Medicine

1994; 330:1476–80. https://doi.org/10.1056/nejm199405263302102.

3. Cooke RWI. Neonatal—perinatal medicine: Diseases of the Fetus and Infant, 5th ed. Avroy A. Fanaroff

and Richard J. Martin, Eds. St. Louis, MO: Mosby Year Book, 1992, 1450 pp. Pediatric Pulmonology

1993;16:207–207. https://doi.org/10.1002/ppul.1950160312.

4. Md RB, Berbano R, Naddaf S, Echemendia E, FACE, Barsa J, et al. USE OF IODINE-123 AS A

DIAGNOSTIC TRACER FOR NECK AND WHOLE-BODY SCANNING IN PATIENTS WITH WELL-DIFFERENTIATED THYROID CANCER. Endocrine Practice 1998;4:11–6.

https://doi.org/10.4158/ep.4.1.11.

5. Asztalos E, Murphy K, Hannah M, Willan A, Matthews S, Ohlsson A, et al. 2: Multiple Courses of

Antenatal Corticosteroids for Preterm Birth Study: 5-Year Outcomes (MACS-5). American Journal of

Obstetrics and Gynecology 2013;208:S2–3. https://doi.org/10.1016/j.ajog.2012.10.176.

6. Hardt KVD, Von Der Hardt K, Schoof E, Kandler MA, Dötsch J, Rascher W. Aerosolized Perfluorocarbon

Suppresses Early Pulmonary Inflammatory Response in a Surfactant-Depleted Piglet Model. Pediatric

Research 2002;51:177–82. https://doi.org/10.1203/00006450-200202000-00009.

7. Concepts of Neonatal ECMO. The Internet Journal of Perfusionists 2001;1. https://doi.org/10.5580/d9.

8. Jobe AH. Post-conceptional age and IVH in ECMO patients. The Journal of Pediatrics 2004;145:A2.

https://doi.org/10.1016/j.jpeds.2004.07.010.

9. Kurl S, Heinonen KM, Kiekara O. The First Chest Radiograph in Neonates Exhibiting Respiratory Distress

at Birth. Clinical Pediatrics 1997;36:285–9. https://doi.org/10.1177/000992289703600506.

10. Beeton ML, Maxwell NC, Davies PL, Nuttall D, McGreal E, Chakraborty M, et al. Role of pulmonary

infection in the development of chronic lung disease of prematurity. European Respiratory Journal

2011;37:1424–30. https://doi.org/10.1183/09031936.00037810.

11. Victora CG, Kirkwood BR, Ashworth A, Black RE, Rogers S, Sazawal S, et al. Potential interventions for

The prevention of childhood pneumonia in developing countries: improving nutrition. The American

Journal of Clinical Nutrition 1999;70:309–20. https://doi.org/10.1093/ajcn/70.3.309.

12. Gantar IŠ, Štucin Gantar I, Babnik J, Derganc M. Role of surfactant inhibitors in amniotic fluid in

respiratory distress syndrome. Journal of Perinatal Medicine 2002;30.

https://doi.org/10.1515/jpm.2002.065.

13. Kinsella JP, Neish SR, Shaffer E, Abman SH. Low-Dose Inhalational Nitric Oxide in Persistent Pulmonary

Hypertension of the Newborn. Survey of Anesthesiology 1994;38:104. https://doi.org/10.1097/00132586-

199404000-00045.

14. Nissen MD. Congenital and neonatal pneumonia. Paediatric Respiratory Reviews 2007;8:195–203.

https://doi.org/10.1016/j.prrv.2007.07.001.

15. Greenough A, Roberton NR. Morbidity and survival in neonates ventilated for the respiratory distress

syndrome. BMJ 1985;290:597–600. https://doi.org/10.1136/bmj.290.6468.597.

16. Conrad SA, Rycus PT, Dalton H. Extracorporeal Life Support Registry Report 2004. ASAIO Journal

2005;51:4–10. https://doi.org/10.1097/01.mat.0000151922.67540.e9.

17. Lin FYC, Brenner RA, Johnson YR, Azimi PH, Philips JB, Regan JA, et al. The effectiveness of risk-based

Intrapartum chemoprophylaxis for the prevention of early-onset neonatal group B streptococcal disease.

American Journal of Obstetrics and Gynecology 2001;184:1204–10.

https://doi.org/10.1067/mob.2001.113875.

18. Leach CL, Fuhrman BP, Morin FC, Rath MG. Perfluorocarbon-associated gas exchange (partial liquid

ventilation) in respiratory distress syndrome A prospective, randomized, controlled study. Critical Care

Medicine 1993;21:1270–8. https://doi.org/10.1097/00003246-199309000-00008.

19. Steinhorn DM, Leach CL, Fuhrman BP, Holm BA. Partial liquid ventilation enhances surfactant

phospholipid production. Critical Care Medicine 1996;24:1252–6. https://doi.org/10.1097/00003246-

199607000-00031.

20. Greenspan JS, Wolfson MR, David Rubenstein S, Shaffer TH. Liquid ventilation of human preterm

neonates. The Journal of Pediatrics 1990;117:106–11. https://doi.org/10.1016/s0022-3476(05)82457-6.

21. Cai J, Su Z, Zhou Y, Shi Z, Xu Z, Liu J, et al. Beneficial effect of exogenous surfactant in infants suffering acute respiratory distress syndrome after cardiac surgery. European Journal of Cardio-Thoracic Surgery 2011. https://doi.org/10.1016/j.ejcts.2011.01.008.

Downloads

Published

31.05.2020

How to Cite

Vijaya Kumaran, G., Sethu, G., & Ganapathy, D. (2020). RESPIRATORY DISTRESS SYNDROME IN INFANTS- AN OVERVIEW. International Journal of Psychosocial Rehabilitation, 24(3), 6022-6029. https://doi.org/10.61841/fz8n1k96